INNER EAR ORGANOIDS FOR THE STUDY OF HUMAN HEARING AND BALANCE
Dr Jackie Ogier
Passe & Williams Post-Doctoral Research Fellow
Audiology and Speech Pathology
University of Melbourne
RESEARCHER PROFILE (Filmed in Melbourne | August 2024)
Dr Jackie Ogier is an auditory neuroscientist, with a research focus on the molecular biology of hair cells, the specialised sensory receptors in the ear that detect sound and balance. She is a postdoctoral research fellow in the laboratory of A/Prof Bryony Nayagam, supported by a prestigious Passe and Williams foundation fellowship.
Dr Ogier completed her PhD in Neuroscience at the University of Melbourne in 2020, where she investigated the pathogenic mechanisms underlying hearing loss and identified a novel molecular target for preventing aminoglycoside-induced hearing damage. She performed this research at the Murdoch Children’s Research Institute under the guidance of A/Prof Paul Lockhart, A/Prof Bryony Nayagam, and Dr Rachel Burt. During this time, she was President of the Research Students Association and a member of the MCRI Honours and Children’s Campus Graduate Research Training Committees. For her service to discipline, she was recognised with the MCRI Rising Star award in 2017.
Dr Ogier then undertook post-doctoral training at the Sunnybrook Research Institute (University of Toronto) with Prof Alain Dabdoub, where she optimised the collection, dissection, and culture of donated human cochleae for single cell sequencing. She also received The University of Toronto’s Dr Ian Witterick Research Prize in Otolaryngology Head & Neck Surgery for her continued ototoxicity research. Jackie subsequently established a collaboration between the Universities of Toronto and Melbourne to develop an “inner ear in a dish” that will accelerate hearing and balance discovery research.
Dr Ogier’s experience broadly spans the genetics of hearing loss, disease modelling, micro dissection, primary cell culture, stem cell culture, organoids, and proteomics. Overall, she aims to generate knowledge of hearing and vestibular sensory biology.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
CASE STUDY Link between levels of extracellular vesicles in the blood and tissue damage caused by diseases
A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.
This study revealed, for the first time, a link between levels of EVs in the blood and tissue damage caused by diseases such as leukaemia.
Researchers hope to leverage the critical new insight to develop a blood test to monitor cancer patients with tissue damage, which could, in future, enhance treatment strategies for blood cancers and other diseases.
-
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
